Platelet Refractoriness
Conditions
Keywords
V-A ECMO, platelet reactivity, ECMO
Brief summary
An observational study in which investigators will observe platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor.
Detailed description
Investigators will perform an observational study in which platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor will be observed. Participants will be divided into three groups: A: patients on V-A ECMO without P2Y12 inhibitors B patients on V-A ECMO with P2Y12 inhibitors with administration of P2Y12 inhibitor at the time of ECMO insertion C: patients on V-A ECMO already recieving P2Y12 inhibitors at the time of ECMO insertion. Blood samples will be taken prior to and at 2, 4, 12, 22, 48, 72 after ECMO insertion and after removal of an ECMO. VerifyNow System will be used to measure platelet agregation (PRU test).
Interventions
DIAGNOSTIC_TESTP2Y12 Platelet Aggregation Inhibitor
Verify now PRU test
Sponsors
University Medical Centre Ljubljana
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* all patients on VA ECMO
Exclusion criteria
* known P2Y12 alergy * thrombocitopenic patents (\< 50\*109/L), * patients treated with eptifibatide ali bivalirudin * patients younger than 18 years * pregnant patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Verify now P2Y12 platelet inhibition | (Time Frame: Hour 2 after VA ECMO insertion) | Platelet inhibition measured by VerifyNow as P2Y12 reaction units (PRU). Platelet reactivity reflects P2Y12 inhibitor effect with higher PRU values showing low P2Y12 response and lower values decreased platelet reactivity due to the effect of a P2Y12 inhibitor. |
Countries
Slovenia
Contacts
Primary ContactMarko Noc, MD, phD
Backup ContactUrsa Mikuz, MD
Outcome results
None listed